REVVITY, INC.
T. Rowe Price Investment Management, an institutional investment adviser, disclosed beneficial ownership of 18,269,089 shares of Revvity Inc common stock, or 16.4% of the class. It reported sole voting power over 17,089,376 shares and sole dispositive power over 18,269,089 shares. The T. Rowe Price Capital Appreciation Fund holds 11,237,061 shares (10.1%).
T. Rowe Price Associates, Inc. filed Amendment No. 4 to a Schedule 13G/A for Revvity Inc. It reported beneficial ownership of 5,526,874 shares, or 5.0% of the class, as of June 30, 2026. The filing lists sole voting power of 5,508,363 shares and sole dispositive power of 5,526,874 shares.
Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.
Over the past 7 days, alphai's AI scored 3 news stories mentioning RVTY (REVVITY, INC.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent RVTY coverage spans earnings and financial news.
In the last 30 days, RVTY insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($9K). The most active reporter was Gonzales Anita, Vice President and CAO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The filing signals a large, concentrated institutional stake, which can affect near-term positioning and sentiment but is not a fundamental catalyst by itself.
This is a disclosed passive stake update above the 5% threshold, which can affect positioning and perceived shareholder support but is not an operational catalyst.
Guidance raise plus stronger Diagnostics and instrument backlog suggests near-term earnings upside, but Signals software decline and China divestment keep execution risk elevated.
Guidance raise plus stronger backlog and AI-instrument demand likely supports RVTY estimates, while Signals software decline and Life Sciences softness remain near-term risks.
Raised FY organic growth and 2H Signals software expectations, with margin/EPS support from a $16M tariff-refund benefit and leverage reduction plan.
alphai scores every news story that mentions RVTY with an AI model for sentiment and relevance, and aggregates insider trades from REVVITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
T. Rowe Price Investment Management, an institutional investment adviser, disclosed beneficial ownership of 18,269,089 shares of Revvity Inc common stock, or 16.4% of the class. It reported sole voting power over 17,089,376 shares and sole dispositive power over 18,269,089 shares. The T. Rowe Price Capital Appreciation Fund holds 11,237,061 shares (10.1%).
2 min readT. Rowe Price Associates, Inc. filed Amendment No. 4 to a Schedule 13G/A for Revvity Inc. It reported beneficial ownership of 5,526,874 shares, or 5.0% of the class, as of June 30, 2026. The filing lists sole voting power of 5,508,363 shares and sole dispositive power of 5,526,874 shares.
2 min readRevvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.
7 min readRevvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.
6 min readRevvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.
6 min readRevvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.
4 min readRevvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.
6 min readRevvity, Inc. (RVTY) revised higher annual guidance, increasing its fiscal 2026 outlook for pro forma adjusted earnings and related revenue expectations, according to the company. A separate report said Revvity’s Q2 bottom line fell to $51.820 million, or $0.47 per share, versus the prior year period.
2 min readRevvity (NYSE: RVTY) reported Q2 CY2026 results. Revenue rose 7.2% year on year to $729.7 million, exceeding analysts’ estimates by 3.2%. Full-year revenue guidance is $2.85 billion at the midpoint, 0.5% above estimates. Non-GAAP EPS was $1.41, 15.9% above consensus.
4 min readREVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pressrelease.htm EX-99.1 Document FOR IMMEDIATE RELEASE August 4, 2026 Revvity Announces Financial Results for the Second Quarter of 2026 • Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth
6 min read
